{"name":"Bioventus","slug":"bioventus","ticker":"BVS","exchange":"NASDAQ","domain":"bioventus.com","description":"Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In a","hq":"Durham, NC","founded":0,"employees":"940","ceo":"Thomas J. Kearney","sector":"Orthobiologics / Medical Devices","stockPrice":10.58,"stockChange":0.18,"stockChangePercent":1.73,"marketCap":"$717M","metrics":{"revenue":576300032,"revenueGrowth":6.6,"grossMargin":68.7,"rdSpend":12113000,"netIncome":22732000,"cash":35846000,"dividendYield":0,"peRatio":25.8,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"DUROLANE patent cliff ($100.0M at risk)","drug":"DUROLANE","type":"patent_expiry","sentiment":"negative"},{"date":"2032-06-01","label":"Euflexxa patent cliff ($50.0M at risk)","drug":"Euflexxa","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Bioventus Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Bioventus reported fourth quarter and full year 2023 financial results, with revenue of $145.4 million and $542.8 million, respectively.","drugName":"","sentiment":"neutral"},{"date":"2023-09-28","type":"deal","headline":"Bioventus Announces Agreement to Acquire Orthofix's Extremities and Biologics Business","summary":"Bioventus announced an agreement to acquire Orthofix's extremities and biologics business, expanding its product portfolio and geographic reach.","drugName":"","sentiment":"positive"},{"date":"2023-06-15","type":"regulatory","headline":"Bioventus Receives FDA Clearance for DUROLANE in the United States","summary":"Bioventus received FDA clearance for DUROLANE in the United States, expanding its product portfolio and market presence.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPa2F5SUxMZ19QQVlaX01VSk10RG5jaGZfWnZpZTg1R3dkMF9CLWtuWktBRnduYllfQTdXaVpmQUJmMGlQX0tmbUVjUDVCWDBiWlVVcGRkeXNBOXpqTzR6OVVRdW13VHNWVVh3bDlkSzVXZmNFU25ESlBvRkNrRnpXbWJRUGxheU9fWUNDbU8tZGtveFh2LW5FWDU5MWZab1l1UjRobjdmVnpoUQ?oc=5","date":"2026-03-24","type":"pipeline","source":"Stock Titan","summary":"Bioventus (BVS) CFO vests 18,625 RSUs with 8,091 shares withheld for taxes - Stock Titan","headline":"Bioventus (BVS) CFO vests 18,625 RSUs with 8,091 shares withheld for taxes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPbzV0VmgyY2lSN29mXzFnQm5RZU1ycjlyQmU5VjFUbklYWnhsUS1SQjIyZ1ExUmFyUzZTTlNEU1JhclBiQW9NM1B4YVJ0R0VYSzg2UzEyaHJSajdFZzNKOFJBRzFjMDY4eUpUekxoeUZabjFnVXRFQTBLWlhEQW5FQTR2bl9scjE1T0FpM01kY3g1UEhJSmdzMDVBYmVfbmhFak9TbjlHaWRTZw?oc=5","date":"2026-03-17","type":"pipeline","source":"Stock Titan","summary":"Bioventus (BVS) CFO receives major stock awards and exercises RSUs - Stock Titan","headline":"Bioventus (BVS) CFO receives major stock awards and exercises RSUs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQTGtGOFlYeklObV96b0NVZkNTaWxDUUpSNm00SnBCdmJnLXV0Q3pHbWZvOERrSXV3R2pJVDdSWG0zbFhzSDFLSkpjejN0R1E4ZThBSmlVeEZweWdGa3Q4c2hTR3FWQWtON1lCZkdTUDhuejI0SVg5SjJsaFc1Q1Z1QXZZakNSb1o0dlpwQVFNcnUwN25VQk54MFZxcU1JUWZzUnM5akYtOGplUQ?oc=5","date":"2026-03-13","type":"pipeline","source":"Stock Titan","summary":"Bioventus (BVS) director logs open-market sale of 12,000 shares - Stock Titan","headline":"Bioventus (BVS) director logs open-market sale of 12,000 shares","sentiment":"neutral"},{"date":"2026-03-05","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPbDVOSEhzcVphNXFMcEZlR2hJVU1IMkYtQWYycDRxRGpWTVNWNHp5Y2xqV1o1TVd0alJoR0RsSV9LV2xYekgyTWlaU0RaQUlHeVBWTnphWXVaRmdUNzlYUnViMW1nVnFjbkJlM09rVjVNQ2M2Q29vdTRmUmV3bTUwM0V6OGx3YWF0TmFtZXZfcWg0VTlSc1FyaWRkVFQ2VUlTbUVtUTZ1UlJMM3pTb1BsRWpiYjEwMHFDdUE?oc=5","date":"2026-02-24","type":"earnings","source":"Stock Titan","summary":"Bioventus sets March 5 call, Q4 2025 earnings and business update - Stock Titan","headline":"Bioventus sets March 5 call, Q4 2025 earnings and business update","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxOZWhoVm91VnJzMkhVcF9aUXV0a0hpU0lWdURpaDBFeFdrTzNYR0hlQ3JfWGdwbUJPZEgxejZQbjJEUzAwT0pBbm9RZzVUOHVZbmxvNlRoTnFJbmI2NXMwMF9sd1ZieUROcUNHN1pjVnFrQ1oyMlVPOHRmUk5VNHRTWGIzNmRKSGZiVFJCaEpjVFpZR2x5LWduZFNjRDN5cFdyLTNjRkNCQ0lIeGVwcHFWUDhBOTBKQQ?oc=5","date":"2026-02-06","type":"pipeline","source":"Kalkine Media","summary":"Bioventus (NASDAQ:BVS) aligns with Nasdaq Composite Index medtech themes - Kalkine Media","headline":"Bioventus (NASDAQ:BVS) aligns with Nasdaq Composite Index medtech themes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPdEN1R19RLVR1Tl9mWG8tVHl3UDRTdWZhYkJnZ2lkdWxmbzhLbFc2dFdud1hoMnNheTRzdXM3S0c4ekFNT184QTM1emd5dU9OM0MzOTR1LVlpWnk1SWlROHZZYndiM2x2TEFqYjFmb1dQaGtSX2NRX1VVejlLMlY0NVlMQk5XR0RfSkdybkdCR0tKbkllNlMwaWRNVkZ1d2k4OUYxcG1wdkh3cjh2d2xsYVJPR21Bdw?oc=5","date":"2026-01-06","type":"pipeline","source":"Stock Titan","summary":"Bioventus CEO to speak at 44th J.P. Morgan healthcare conference, online - Stock Titan","headline":"Bioventus CEO to speak at 44th J.P. Morgan healthcare conference, online","sentiment":"neutral"},{"date":"2025-11-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE9IblgzcUlpVHM5MWtlWHhRdFE2Qk8yckJDLTJEQ3ZWV1hPaTVkcDJVbFI4bG9EeFl1TDA2ZlVUdnd4bVZwRWhVS255UkFLVDdnREpndEJPOUhuaUJ5dm8tWldRRmhXM25WaXlNNGxGZjZfTTVZb1o2SzRjWQ?oc=5","date":"2025-05-07","type":"earnings","source":"Yahoo Finance","summary":"Bioventus Inc (BVS) Q1 2025 Earnings Call Highlights: Navigating Growth Amidst Divestitures - Yahoo Finance","headline":"Bioventus Inc (BVS) Q1 2025 Earnings Call Highlights: Navigating Growth Amidst Divestitures","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQSnJFZkRYZ0s4WWpqMGpNdzNlTXhQX2RCb1A1TGNPY00wbTJaZk4tNWNJV0tXTW9iOVdzS19DdVV1N0xvV1ZJaDV0U2lEeHBQYXFVUjRfUURHNHpUZlF0Z0ZhMHk2enVDVTBLcTlUUjBpWkgzRVJZS3BnWTB5WGo2YU1ISkFRVVZY?oc=5","date":"2024-10-07","type":"pipeline","source":"Yahoo Finance","summary":"Sage Therapeutics Stock Down Almost 40% in 3 Months: Here's Why - Yahoo Finance","headline":"Sage Therapeutics Stock Down Almost 40% in 3 Months: Here's Why","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxONkNUNnh1WHpwc0UwZHU2Z0JqSVJiWm9OTi1XMGR6dWtDRlNCTXR6WElCQlVyUmxfZzJTMnR2T3hNdnhrLWZpYXlJX3FTeVpCR3Rnc0RBR2lxR3pEbXFYaFR0c09XTlc4bE55eTZPUzhnQTJzcjA2Q2JjSXRDNm9Jcg?oc=5","date":"2020-10-22","type":"pipeline","source":"MarketBeat","summary":"Top Profound Medical (PROF) Competitors 2026 - MarketBeat","headline":"Top Profound Medical (PROF) Competitors 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxNT2c3WlMxMTUyQTM5T190YkpxUkIxWnYtY0p3cnFxZEtxRVNZMmxSRXRaZDJ4Zi0tSmJvX0hGcGFlY0JlNWpyWTFXemRsbXhDX0hrbDN1Vks2ODlLVzNNT2FaMmp2REtnU0VpNW15MFotc0h2QnVyR0F4Z2RrSWJBbQ?oc=5","date":"2020-05-02","type":"pipeline","source":"MarketBeat","summary":"Top KORU Medical Systems (KRMD) Competitors 2026 - MarketBeat","headline":"Top KORU Medical Systems (KRMD) Competitors 2026","sentiment":"neutral"}],"patents":[{"drugName":"DUROLANE","drugSlug":"sodium-hyaluronate","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":100000000},{"drugName":"Euflexxa","drugSlug":"hylan-g-f-20","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":50000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Smith & Nephew","Stryker","Zimmer Biomet"],"therapeuticFocus":["Orthobiologics","Musculoskeletal Health"],"financials":{"source":"sec_edgar+yahoo","revenue":568087000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":568087000,"period":"2025-12-31"},{"value":573280000,"period":"2024-12-31"},{"value":573280000,"period":"2024-12-31"},{"value":512345000,"period":"2023-12-31"},{"value":512345000,"period":"2023-12-31"}],"grossProfit":388157000,"grossProfitHistory":[{"period":"2025-12-31","value":388157000},{"period":"2024-12-31","value":388226000},{"period":"2023-12-31","value":328193000},{"period":"2022-12-31","value":331080000}],"rdSpend":12113000,"rdSpendHistory":[{"period":"2025-12-31","value":12113000},{"period":"2024-12-31","value":13951000},{"period":"2023-12-31","value":13446000},{"period":"2022-12-31","value":23854000}],"sgaSpend":314026000,"operatingIncome":56291000,"operatingIncomeHistory":[{"period":"2025-12-31","value":56291000},{"period":"2024-12-31","value":22825000},{"period":"2023-12-31","value":2026000},{"period":"2022-12-31","value":-34656000}],"netIncome":22732000,"netIncomeHistory":[{"period":"2025-12-31","value":22732000},{"period":"2024-12-31","value":-36125000},{"period":"2023-12-31","value":-156230000},{"period":"2022-12-31","value":-158704000}],"eps":-0.52,"epsHistory":[{"period":"2024-12-31","value":-0.52},{"period":"2023-12-31","value":-2.49},{"period":"2022-12-31","value":-2.59},{"period":"2021-12-31","value":-0.15}],"cash":51238000,"cashHistory":[{"period":"2025-12-31","value":51238000},{"period":"2024-12-31","value":41582000},{"period":"2023-12-31","value":36964000},{"period":"2022-12-31","value":30186000}],"totalAssets":683559000,"totalLiabilities":455112000,"totalDebt":293951000,"equity":184105000,"operatingCashflow":74673000,"operatingCashflowHistory":[{"period":"2025-12-31","value":74673000},{"period":"2024-12-31","value":38795000},{"period":"2023-12-31","value":15344000},{"period":"2022-12-31","value":-13537000}],"capex":-2562000,"capexHistory":[{"period":"2025-12-31","value":-2562000},{"period":"2024-12-31","value":-1006000},{"period":"2023-12-31","value":-7362000},{"period":"2022-12-31","value":-1478000}],"freeCashflow":72111000,"dividendsPaid":0,"buybacks":null,"employees":940,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":82757000,"ebit":19449000,"ebitda":31143000,"period":"2025-12-31","revenue":157900000,"epsBasic":0.22,"netIncome":14755000,"rdExpense":3007000,"epsDiluted":0.21,"grossProfit":108782000,"operatingIncome":21721000},{"sga":78657000,"ebit":10847000,"ebitda":22250000,"period":"2025-09-30","revenue":138651000,"epsBasic":0.05,"netIncome":3155000,"rdExpense":2923000,"epsDiluted":0.05,"grossProfit":94229000,"operatingIncome":11251000},{"sga":79110000,"ebit":17807000,"ebitda":29856000,"period":"2025-06-30","revenue":147660000,"epsBasic":0.11,"netIncome":7459000,"rdExpense":3172000,"epsDiluted":0.11,"grossProfit":102090000,"operatingIncome":18369000},{"sga":73502000,"ebit":4092000,"ebitda":15957000,"period":"2025-03-31","revenue":123876000,"epsBasic":-0.04,"netIncome":-2637000,"rdExpense":3011000,"epsDiluted":-0.04,"grossProfit":83056000,"operatingIncome":4950000},{"sga":86613000,"ebit":9229000,"ebitda":21634000,"period":"2024-12-31","revenue":153642000,"epsBasic":0,"netIncome":-156000,"rdExpense":3246000,"epsDiluted":0,"grossProfit":102656000,"operatingIncome":11029000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":10.58,"previousClose":10.4,"fiftyTwoWeekHigh":11.25,"fiftyTwoWeekLow":5.81,"fiftyTwoWeekRange":"5.81 - 11.249","fiftyDayAverage":9.49,"twoHundredDayAverage":7.92,"beta":0.72,"enterpriseValue":1002517696,"forwardPE":11.7,"priceToBook":3.79,"priceToSales":1.24,"enterpriseToRevenue":1.74,"enterpriseToEbitda":12.39,"pegRatio":1.37,"ebitda":80897000,"ebitdaMargin":14,"freeCashflow":63310876,"operatingCashflow":102938000,"totalDebt":288420000,"debtToEquity":123.1,"currentRatio":1.69,"returnOnAssets":5.6,"returnOnEquity":16.5,"analystRating":"1.4 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":5,"targetMeanPrice":14.8,"targetHighPrice":16,"targetLowPrice":14,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":11.3,"institutionHeldPercent":80.2,"sharesOutstanding":67748048,"floatShares":33710751,"sharesShort":1465399,"shortRatio":3.28,"shortPercentOfFloat":2.2,"epsTrailing":0.41,"epsForward":0.9,"revenuePerShare":8.61,"bookValue":2.79,"officers":[{"age":52,"name":"Mr. Robert E. Claypoole","title":"President, CEO & Director"},{"age":55,"name":"Mr. Mark L. Singleton","title":"Senior VP & CFO"},{"age":64,"name":"Mr. Anthony  D'Adamio J.D.","title":"Senior VP, General Counsel & Corporate Secretary"},{"age":null,"name":"Mr. Mike  Crowe B.S., M.B.A.","title":"Senior Vice President of Operations"},{"age":null,"name":"Mr. David  Crawford","title":"Vice President of Investor Relations & Treasurer"},{"age":63,"name":"Ms. Katrina J. Church J.D.","title":"Senior VP & Chief Compliance Officer"},{"age":null,"name":"Ms. Helen  Leupold","title":"Senior VP & Chief Human Resources Officer"},{"age":null,"name":"Mr. Dave  Venner","title":"Senior VP & GM of Surgical"}],"industry":"Medical Devices","irWebsite":"","website":"https://www.bioventus.com","phone":"919 474 6700"}}